Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo- (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MR-107A-02 (Primary) ; Tramadol
Indications Postoperative pain
Focus Registrational; Therapeutic Use
Sponsors Mylan Specialty

Most Recent Events

01 Aug 2025 According to a Viatris media release, data from the trial will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025.
08 May 2025 Primary endpoint (Summed Pain Intensity Difference (SPID) for MR-107A-02 versus placebo.) has been met, according to a Viatris media release.
08 May 2025 Results presented in a Viatris Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com